The inter-relations of steroid hornone levels in plasma from mothers and their undisturbed fetuses during the second trimester of human pregnancy have not been defined previously. Maternal vein (HV), fetal artery (FA), fetal vein (FV) and amniotic fluid (AF) levels of progerterone (P), 17-OHP, 11 deoxycortisol (S), DOC, cortisone (E). cortisol (P), corticosterone (B) and aldosterone (Aldo) were wssured in microassays in 12 conscious but sedated mothers and their fetuses undergoing therapeutic termination of pregnancy at 16-20 weeks gestation. The study received the approval of the Eospital Ethical. Committee and maternal consent for the studies was obtained in each case. FA and W samples vere obtained by direct vessel puncture through a fetoacope without fetal disturbance. PA levels of F and B were significantly higher (pt0.01) than in W ; W levels of P and E vere higher (p<0.01) than FA values. No significant differences betveen FV or FA were found for levels of DOC, 17-OHP or S. HV levels of Aldo, P and B were significantly higher, with values of P, 17-OHP, WC and S significantly lovqr than those in either fetal vessel.
AF values of F, B. S. Aldo and DOC tended to be lower than those reported previourly from mothers undergoing routine amniocentesis. We conclude: there is evidence that the fetal adrenal cortex is functioning independently of the mother in mid-gestation; rsternal premedication may lower fetal stress hormone secretion. to 118.8 2 11.5 pglml for the latter between the 15-20 weeks and 20-34 weeks periods. A significant relationship between AF levels and age of pregnancy could only be detected for GAldo (r= 0.691, p<0.01). Our results agree with patterns of PAldo (Weir et al, 1974 , Ledoux et al, 1975 and FAldo (Blankstein et al, 1980 , Sippell et al, 1981 already reported. The increase of GAldo presently described disagrees with its high and stable level reported by Aderjan et a1 (1977) on poorly documented data. Simultaneous determination of F-and G-Aldo shows that the rate of increase of fetal aldosterone production is higher than could be expected f r m estimation of FAldo alone. Augmentation of GAldo in AF probably expresses both the increased contribution of urine to AF and the maturation of renal glycuronoconjugation process. We studied the role of AVP in the water metabolism of preterm infants with a sensitive urinaw AVP RIA.Three groups were studie d.GroupA:l6 orally fed infants f m 32 to 38 weeks of gestation. GmupB:6 infants with parenteral fluid administration f m m 32 to 36 weeks of gestation.GmupC:lZ infants,ventilated for RDS f m 28 to 36 weeks of gestation with parenteral fluid administration. Gr.A received 5@9 ml/kg on day 1 with daily increasing m u n t s -up to 169+17 m l A g on day 7 p.o.They had wall urine volumes with high omiality and lost up to 9% weight.AVP was stirmlated by this water loss f m 15.3+4.3pg/ml on day 1 to 36.6+27.2pg/ml on day 3-5.GI.8 received initTally greater fluid volumes i.v. (109+10 ml/kg onday 11.They produced mre urine with low omlality and did not loose weight.AVP was suppressed f m 13.1+11.4pg/ml on day 1 to 5.4+3.5pg/ml on day 2.GrC received on day 1 already 121 +21ml/kg.~he-infants gained weight up to 107.5+6.3% on day 3while -s e m Na decreased to 133 ml/l.Urine volume was inadequate low as was urine omlality inadequate high.AVP was 21.0+18.7pg/ml on day 1 and was not suppressable until day 3.There was a significant (p=O.O5)correlation between IminApgar scores and AVP as well as FiO2 and AVP on day ?.No significant correlation was found between m a n respiratory pressure and AVP.We conclude,that infants with RDS have a nonosnotic release of AVP and should receive smaller fluid volumes in the first three days of life.
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GFCWI?l HORHONE (GH) RFSPONSE TO THYROTFOPIN-RELEASING HORMONE (TRH) DURING PUBEFTY: A REAPPRAISAL.
A paradoxical GH response to TRH has been described in constitutional tall'stature. Bronacriptine (BR) therapy has consequently been proposed to reduce adult height prediction in tall but otherwise normal children. This study evaluates the GH response (0-180min) to a single dose (0.2mg) of TRH (n=59) in 11 tall children followed prospectively before (Al) and after (A2) 6 months of treatment with BR (Srng/d), while still on therapy, in 9 children of average height (B), 12 with precocious puberty (C), 9 with delayed puberty (D) and 7 with GH deficiency (E). Peaks of GH 0 5ng/ml) were observed in 92.3% of cases from groups A to D, whereas none occurred in group E. They occurred mainly beyond 120 minutes (57.6%) and were of similar magnitude in groups Al, A2 and B..In addition, a bifid secretion pattern occurred in 43.5% of cases. In these patients, the early peak was unrelated to stress (normal prolactin). In conclusion, the mode of GH response as well as GH peak amplitude following TRH remain similar in tall and in average height children who are matched for bone age. In group A2, BR failed to modify the GH secretory pattern following TRH injection. The pattern of GH secretion observed after TRH might be the expression of its nonnal amplified pulsatile secretion mode during puberty and thus be independent of TRH.
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THE MECHANISM OF THE ADOLESCENT GROWTH SPURT INDUCED BY PULSATILE GnRH TREATMENT We have induced puberty in 26 patients (12M, 14F) using low dose pulsatile GnRH for 0.8 to 1.6 years. Progress was monitored by serial overnight profiles for gonadotrophins, GH and sex steroids at 15 minute intervals. GnRH 2 or 4ugs was administered subcutaneously at night at 90 minute intervals. In order to maintain normal pubertal development, GnRH pulse amplitude was progressively increased and/or treatment was administered throughout 24 hrs. We have succeeded in mimicking all the endocrine and clinical events of puberty including the timings of the adolescent growth spurts.
Girls showed early growth acceleration with an increase in GH secretion from the first week of treatment. After breast stage 4 had been attained, GH pulse amplitude varied with the state of ovarian follicular development. By contrast, boys showed a decelerating growth velocity and diminishing GH pulse amplitude at the start of treatment, even though sex steroid secretion increased progressively. When a lOml testicular volume had been attained there was a marked increase in GH pulse amplitude coincident with the pubertal growth spurt. In both sexes GH secretion was modulated by changes in pulse amplitude without alteration in pulse frequency.
These observations explain the differences in timings of the onset of the adolescent growth spurts of girls and boys. After completion of growth hormone (GH) treatment, 19 patlent:, wlth Isolated "ldlopathlc" growth hormone deflclency (IGHD) and 15 wlth post-lrradlatlon growth hormone deflclency (PRGHD) were asked to undergo rctestlng of GH secretion wlth an lnsulln tolerance test and/or an arglnlne stlmulatlon test. PRGHD patlents are those wlth CNS tumours dlstant from thehypothalamlcpltultary axls (n-13) or acute lymphatic leukaemia (n=2), who had received cranlalorcranospinal ~rradlatlon.
All 15 patients wlth PRGHD remalned GH deflclent [peak GH level <7mU/1 (n.10) and 7-15mU/1 (n=5)].
However of the 19 retested IGHD patlents, 5 (26%) had peak GH responses >15mU/1 (regarded now as translent or false F-IGD) and were lndlstirigulshable from the remainder [permanent or true 1-IGHD, peak GH levels <7mU/1 (nz12) and 7-15 mU/1 (n:2)] by pre-treatment anthropometry and post-treatment helght SDS, but had a lower first year helght velocity (Mean Veloclty 5.4crn/yr i0.9 for F-IGHD v 8.7cm/year k1.75 for T-IGHD p<D.DI) and height acceleration on treatment (Mean acceleration 2.lcm/yr i1.7 for F-IGHD v 5.2cm/yr i2.3 for T-IGHD ~~0.05). By current practices 2 F-IGHD patlents may have been dlstingulshed by sex-sterold prlmlng.
Thus post-lrradlatlon GH deflclency appears to be permanent but errors of diagnosis in IGHD are commoli.
